MLN0128 (INK128), an Investigational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with Relapsed or Refractory Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL), or Waldenstrom Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose-Escalation Study

被引：1
|
作者：
Ghobrial, Irene M. [1 ,2 ]
Siegel, David [3 ]
Vij, Ravi [4 ]
Wolf, Jeffrey L. [5 ]
Berdeja, Jesus G. [6 ]
Matous, Jeffrey V. [7 ]
Lipman, Peter [8 ]
Patel, Chirag [8 ]
Le, Trinh [9 ]
Rommel, Christian [9 ]
Berk, Gregory [8 ]
机构：
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA
[3] Hackensack Univ Med Ctr, Hackensack, NJ USA
[4] Washington Univ Sch Med, Div Oncol, Dept Med, St Louis, MO USA
[5] Univ Calif San Francisco, San Francisco, CA 94143 USA
[6] Sarah Cannon Res Inst, Nashville, TN USA
[7] Colorado Blood Canc Inst, Denver, CO USA
[8] Millennium Pharmaceut Inc, Cambridge, MA USA
[9] Intellikine LLC, La Jolla, CA USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.4038.4038
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4038
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial
    Korfi, Koorosh
    Christiansen, Ailsa
    Jiang, Zhiwen
    Wilson, Sabine
    Tracy, Samuel
    Blank, Annika
    Herter, Sylvia
    Dimier, Natalie
    Gomes, Bruno
    Umana, Pablo
    Ghesquieres, Herve
    Houot, Roch
    Offner, Fritz
    Walter, Harriet
    Bartlett, Nancy L.
    Cartron, Guillaume
    Dickinson, Michael
    Townsend, William
    Gritti, Giuseppe
    Albareda, Francesc Bosch
    Morschhauser, Franck
    Hutchings, Martin
    Carlo-Stella, Carmelo
    Lechner, Katharina
    BLOOD, 2023, 142
  • [22] Interim results from a dose-escalation study of the BCL-2 inhibitor venetoclax (ABT-199/GDC-0199) plus bendamustine (B) and rituximab (R) in patients (pts) with relapsed/refractory (R/R) Non-Hodgkin's Lymphoma (NHL)
    De Vos, Sven
    Flowers, Christopher
    Wang, Ding
    Swinnen, Lode J.
    Fowler, Nathan Hale
    Reid, Erin G.
    Cordero, Jaclyn
    Gifford, Maryella
    D'Amico, Diane
    Dunbar, Martin
    Zhu, Ming
    Salem, Ahmed H.
    Enschede, Sari H.
    Ricker, Justin L.
    Chien, David
    Humerickhouse, Rod
    Kozloff, Mark
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] A Phase 1, Open-Label, Dose-Escalation and Expansion, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169 in Patients with Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma
    Dholaria, Bhagirathbhai
    Mamuye, Admasu
    Yurewicz, Diana
    Dabovic, Kristina
    Yuet, Amy
    Abonour, Rafat
    Kelly, Kevin R.
    Voorhees, Timothy J.
    Kazandjian, Dickran
    BLOOD, 2022, 140 : 12621 - 12622
  • [24] Phase 1 Study of TAK-659, an Investigational Reversible Dual SYK/FLT-3 Inhibitor, in Patients (Pts) with Lymphoma: Updated Results from Dose-Escalation and Expansion Cohorts
    Kaplan, Jason
    Gordon, Leo I.
    Rambaldi, Alessandro
    Gritti, Giuseppe
    Popat, Rakesh
    Burris, Howard A.
    Patel, Manish R.
    Madan, Sumit
    Chau, Ian
    Radford, John A.
    Iyer, Swami P.
    De Oteyza, Jaime Perez
    Zinzani, Pier Luigi
    Wang, Shining
    Sheldon-Waniga, Emily
    Stumpo, Kate
    Shou, Yaping
    Carpio, Cecilia
    Bosch, Francesc
    BLOOD, 2017, 130
  • [25] Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin's lymphoma (B-NHL).
    Budde, L. Elizabeth
    Ghosh, Nilanjan
    Chavez, Julio C.
    Lossos, Izidore S.
    Mehta, Amitkumar
    Dorritie, Kathleen Anne
    Kamdar, Manali K.
    Negricea, Raluca
    Pham, Song
    Hristopoulos, Maria
    Huw, Ling-Yuh
    O'Hear, Carol Elaine
    Oki, Yasuhiro
    To, Iris
    Diefenbach, Catherine S. Magid
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [26] Abexinostat (S78454/PCI-24781), an Oral Pan-Histone Deacetylas (HDAC) Inhibitor in Patients with Refractory or Relapsed Hodgkin's Lymphoma, Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. Results of a Phase I Dose-Escalation Study in 35 Patients
    Morschhauser, Franck
    Terriou, Louis
    Coiffier, Bertrand
    Salles, Gilles
    Kloos, Ioana
    Tavernier, Nicolas
    Depil, Stephane
    Ribrag, Vincent
    BLOOD, 2012, 120 (21)
  • [27] Anti Tumor Activity Of Selinexor (KPT-330), A First-In-Class Oral Selective Inhibitor Of Nuclear Export (SINE) XPO1/CRM1 Antagonist In Patients (pts) With Relapsed / Refractory Multiple Myeloma (MM) Or Waldenstrom's Macroglobulinemia (WM)
    Chen, Christine I.
    Gutierrez, Martin
    Brown, Peter de Nully
    Gabrail, Nashat
    Baz, Rachid
    Reece, Donna E.
    Savona, Michael
    Trudel, Suzanne
    Siegel, David S.
    Mau-Sorensen, Morten
    Kuruvilla, John
    Byrd, John C.
    Shacham, Sharon
    Rashal, Tami
    Yau, Cindy Y. F.
    McCauley, Dilara
    Landesman, Yosef
    Klebanov, Boris
    Pond, Greg
    Oza, Amit M.
    Kauffman, Michael
    Mirza, Mansoor R.
    BLOOD, 2013, 122 (21)
  • [28] A DOSE-ESCALATION STUDY OF THE BCL-2 INHIBITOR VENETOCLAX (ABT-199/GDC-0199) PLUS BENDAMUSTINE (B) AND RITUXIMAB (R) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) NON-HODGKIN'S LYMPHOMA (NHL)
    de Vos, S.
    Flowers, C.
    Wang, D.
    Swinnen, L.
    Fowler, N.
    Reid, E.
    Cordero, J.
    Gifford, M.
    D'Amico, D.
    Dunbar, M.
    Zhu, M.
    Salem, A.
    Enschede, S. H.
    Ricker, J. L.
    Chien, D.
    Humerickhouse, R.
    Kozloff, M.
    HAEMATOLOGICA, 2015, 100 : 4 - 5
  • [29] Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase Ib/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Budde, Elizabeth
    Ghosh, Nilanjan
    Chavez, Julio
    Lossos, Izidore S.
    Mehta, Amitkumar
    Dorritie, Kathleen
    Kamdar, Manali
    Negricea, Raluca
    Song Pham
    Hristopoulos, Maria
    Huw, Ling-Yuh
    O'Hear, Carol
    Oki, Yasuhiro
    To, Iris
    Diefenbach, Catherine
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S393 - S394
  • [30] Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
    Younes, Anas
    Berdeja, Jesus G.
    Patel, Manish R.
    Flinn, Ian
    Gerecitano, John F.
    Neelapu, Sattva S.
    Kelly, Kevin R.
    Copeland, Amanda R.
    Akins, Amy
    Clancy, Myles S.
    Gong, Lucy
    Wang, Jing
    Ma, Anna
    Viner, Jaye L.
    Oki, Yasuhiro
    LANCET ONCOLOGY, 2016, 17 (05): : 622 - 631
12345